Literature DB >> 11272892

Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression.

R R Tubbs1, J Pettay, P Roche, M H Stoler, R Jenkins, J Myles, T Grogan.   

Abstract

We sought the validation of a three-color fluorescence-based system that simultaneously profiles Her2/neu oncogene copy by fluorescence in situ hybridization (FISH) and Her-2/neu encoded protein by the use of a versatile alkaline phosphatase chromogen fast red K in either fluorescence or bright-field mode. Nuclei were counterstained with DAPI. Nineteen infiltrating ductal carcinomas of breast were comprehensively evaluated for Her-2/neu amplification/overexpression by direct and indirect FISH using digoxigenin (DigFISH) and direct fluorescently labeled probes, autoradiographic RNA:RNA in situ hybridization, and immunohistochemistry using monoclonal antibody CB11. CODFISH results correlated well with DigFISH, direct-label FISH, mRNA expression, and oncoprotein expression as assessed with CB11, and enabled simultaneous visualization of gene copy and protein. In addition, qualitative immunohistochemistry may be followed by CODFISH gene copy enumeration to clarify ambiguous cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11272892      PMCID: PMC1906899          DOI: 10.1016/S1525-1578(10)60620-4

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  12 in total

1.  Increased HER2 with U.S. Food and Drug Administration-approved antibody.

Authors:  P C Roche; J N Ingle
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 2.  HER-2/neu oncogene amplification and expression in breast and ovarian cancers.

Authors:  M F Press; L A Jones; W Godolphin; C L Edwards; D J Slamon
Journal:  Prog Clin Biol Res       Date:  1990

3.  In situ hybridization analysis of lymphoproliferative disorders. Assessment of clonality by immunoglobulin light-chain messenger RNA expression.

Authors:  G H Segal; H E Shick; R R Tubbs; A J Fishleder; M H Stoler
Journal:  Diagn Mol Pathol       Date:  1994-09

4.  The "CD43 only" phenotype. An aberrant, nonspecific immunophenotype requiring comprehensive analysis for lineage resolution.

Authors:  G H Segal; M H Stoler; R R Tubbs
Journal:  Am J Clin Pathol       Date:  1992-06       Impact factor: 2.493

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

Authors:  T W Jacobs; A M Gown; H Yaziji; M J Barnes; S J Schnitt
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

Authors:  G Pauletti; W Godolphin; M F Press; D J Slamon
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.

Authors:  R M Bukowski; T Olencki; H Gunn; D McLain; G T Budd; K Sandstrom; L Tuason; C Redovan; P Rayman; R Tubbs; D Resta; P Elson; J Finke
Journal:  Clin Cancer Res       Date:  1996-02       Impact factor: 12.531

10.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

Authors:  M F Press; G Hung; W Godolphin; D J Slamon
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

View more
  7 in total

1.  Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.

Authors:  Raymond Tubbs; James Pettay; Marek Skacel; Richard Powell; Mark Stoler; Patrick Roche; James Hainfeld
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

2.  Novel bright field molecular morphology methods for detection of HER2 gene amplification.

Authors:  Raymond Tubbs; James Pettay; David Hicks; Marek Skacel; Richard Powell; Tom Grogan; James Hainfeld
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

3.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.

Authors:  S A Vaziri; R R Tubbs; G Darlington; G Casey
Journal:  Mol Pathol       Date:  2001-08

4.  An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning.

Authors:  Raymond R Tubbs; Eric Swain; James D Pettay; David G Hicks
Journal:  J Mol Histol       Date:  2007-01-09       Impact factor: 3.156

5.  Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically-defined cell populations for gated genotyping.

Authors:  Raymond R Tubbs; Kingshuk Das; James R Cook; James D Pettay; Patrick C Roche; Thomas Grogan
Journal:  J Mol Histol       Date:  2007-01-05       Impact factor: 3.156

6.  Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.

Authors:  Yuefeng Wang; Julia Y S Tsang; Yongmei Cui; Ji Cui; Ying Lin; Songli Zhao; Patrick T W Law; Sai Yin Cheung; Enders K O Ng; Gary M K Tse; Zunfu Ke
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

7.  Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

Authors:  Marc van de Vijver; Michael Bilous; Wedad Hanna; Manfred Hofmann; Petra Kristel; Frédérique Penault-Llorca; Josef Rüschoff
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.